T
Tetraphase Pharmaceuticals
Biotech & Life Sciences · Watertown, United States · Founded 2006
Antibiotics to treat multi-drug resistant bacterial infections MoreLess
Tetraphase Pharmaceuticals is dedicated to addressing one of the most critical threats to global health: antibiotic resistance. The company specializes in the development of novel antibiotics aimed at treating infections caused by multidrug-resistant (MDR) bacteria. Utilizing proprietary chemistry technology, Tetraphase is creating multiple tetracycline-based antibiotics that show promise against some of the most challenging MDR bacteria. The company's mission is to make these innovative antibiotics accessible to all patients who need them, thereby potentially changing the course of antibiotic resistance for millions at risk.
Tetraphase operates in the pharmaceutical and biotechnology market, primarily serving healthcare providers, hospitals, and patients who are in dire need of effective treatments against resistant bacterial infections. The business model revolves around research and development (R&D) of new antibiotic drugs, followed by clinical trials, regulatory approvals, and eventual commercialization. Revenue is generated through the sale of these antibiotics, as well as potential out-licensing agreements for their pipeline products.
Keywords: antibiotic resistance, multidrug-resistant bacteria, tetracycline-based antibiotics, proprietary chemistry, healthcare providers, biotechnology, pharmaceutical R&D, clinical trials, regulatory approvals, out-licensing.
Company overview
Tetraphase Pharmaceuticals company information
The essential company record, classifications and operating signals in one place.
- Status
- Acquired
- Founded
- 2006
- Headquarters
- Watertown, United States
- Employees
- 13
- Open positions
- None listed
- Dealroom signal
- 70.8
Valuation & funding
Tetraphase Pharmaceuticals funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| ACQUISITIONOther financing | Jul 2020 | $43M | $43M | La jolla Pharmaceutical | — |
| ACQUISITIONOther financing | Mar 2020 | $14M | $14M | Talphera | ↗ |
| GRANTOther financing | Apr 2017 | $4M | — | CARB-X | — |
| IPOOther financing | Mar 2013 | $0 | — | Undisclosed | — |
| GROWTH EQUITY VCOther financing | Jan 2012 | $0 | — | Undisclosed | — |
| SERIES COther financing | Jun 2010 | F-Prime · CMEA Capital · Excel Venture Management · Skyline Ventures | — | ||
| SERIES BOther financing | Sep 2009 | Skyline Ventures · Flagship Pioneering · Mediphase Venture Partners · F-Prime | — | ||
| SERIES AOther financing | Aug 2008 | Undisclosed | — | ||
| SERIES AOther financing | Nov 2006 | Mediphase Venture Partners | — | ||
| SPINOUTOther financing | Jan 2006 | Harvard University | — |
Financials
Revenue, earnings and profit over time
Reported history and available estimates. Estimated years are marked “E”; sparse fields are left blank rather than inferred.
| Year | Revenue | Growth | EBITDA | Margin |
|---|---|---|---|---|
| 2026 | $22M | 0% | −$18M | -81.8% |
| 2025 | $22M | 0% | −$18M | -81.8% |
| 2024 | $22M | 0% | −$18M | -81.8% |
| 2023 | $22M | 0% | −$18M | -81.8% |
| 2022 | $22M | +37.5% | −$18M | -81.8% |
| 2021 | $16M | +60% | −$18M | -112.5% |
| 2020 | $10M | — | −$29M | -290% |
Growth signals
Tetraphase Pharmaceuticals website traffic
Latest recorded traffic for Tetraphase Pharmaceuticals is 240 monthly website visits, up 500% over the last three months. Tetraphase Pharmaceuticals's team declined 48% over the past year.
Comparisons
Tetraphase Pharmaceuticals compared with similar companies
Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.
Talent graph
Tetraphase Pharmaceuticals's talent
Source: Dealroom Talent Intelligence.
Investors
15 investors on Tetraphase Pharmaceuticals's cap table
Sourced from Dealroom's funding and investor records. Investor profile links are shown where available.
Global footprint
Where Tetraphase Pharmaceuticals has talent and traffic
team presence
In the news
Latest news about Tetraphase Pharmaceuticals
Recent press, funding announcements, and product moves mentioning Tetraphase Pharmaceuticals — open to read from the original sources.
Market sentiment
What the market is saying about Tetraphase Pharmaceuticals
An AI-synthesized read of the highest-engagement posts about Tetraphase Pharmaceuticals on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Tetraphase Pharmaceuticals’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.